{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:59:38Z","timestamp":1790254778184,"version":"4.1.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41575-026-01226-4","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:24:31Z","timestamp":1782818671000},"page":"791-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells"],"prefix":"10.1038","volume":"23","author":[{"given":"Markus F.","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-2969","authenticated-orcid":false,"given":"Saurabh","family":"Mehandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","volume":"67","author":"I Arijs","year":"2018","unstructured":"Arijs, I. et al. Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 67, 43\u201352 (2018).","journal-title":"Gut"},{"key":"1226_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7549","volume":"9","author":"P Canales-Herrerias","year":"2024","unstructured":"Canales-Herrerias, P. et al. Gut-associated lymphoid tissue attrition associates with response to anti-\u03b14\u03b27 therapy in ulcerative colitis. Sci. Immunol. 9, eadg7549 (2024).","journal-title":"Sci. Immunol."},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1080\/00365521.2021.1946588","volume":"56","author":"M Attauabi","year":"2021","unstructured":"Attauabi, M. et al. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand. J. Gastroenterol. 56, 1040\u20131048 (2021).","journal-title":"Scand. J. Gastroenterol."},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699\u2013710 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 369, 711\u2013721 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR6","first-page":"341","volume":"29","author":"JD Feuerstein","year":"2016","unstructured":"Feuerstein, J. D., Akbari, M., Tapper, E. B. & Cheifetz, A. S. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann. Gastroenterol. 29, 341\u2013347 (2016).","journal-title":"Ann. Gastroenterol."},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N. Engl. J. Med. 362, 1383\u20131395 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan, B. G. et al. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol. Hepatol. 8, 307\u2013320 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","volume":"3","author":"BG Feagan","year":"2018","unstructured":"Feagan, B. G. et al. Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol. Hepatol. 3, 671\u2013680 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr.","year":"2023","unstructured":"Loftus, E. V. Jr. et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 388, 1966\u20131980 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01008-6","author":"MF Neurath","year":"2024","unstructured":"Neurath, M. F. Strategies for targeting cytokines in inflammatory bowel disease. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-024-01008-6 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1226_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt, B. et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 433\u2013446 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese, S. & Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 365, 1713\u20131725 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63","volume":"7","author":"G Roda","year":"2016","unstructured":"Roda, G., Jharap, B., Neeraj, N. & Colombel, J. F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol. 7, e135 (2016).","journal-title":"Clin. Transl. Gastroenterol."},{"key":"1226_CR15","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/biomedicines13081928","volume":"13","author":"T Knezevic Ivanovski","year":"2025","unstructured":"Knezevic Ivanovski, T. et al. Is deep remission the right time to de-escalate biologic therapy in IBD? A single-center retrospective study. Biomedicines 13, 1928 (2025).","journal-title":"Biomedicines"},{"key":"1226_CR16","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/biomedicines12081839","volume":"12","author":"I Faggiani","year":"2024","unstructured":"Faggiani, I. et al. Extraintestinal manifestations in inflammatory bowel disease: from pathophysiology to treatment. Biomedicines 12, 1839 (2024).","journal-title":"Biomedicines"},{"key":"1226_CR17","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1097\/MIB.0000000000000148","volume":"20","author":"I Molendijk","year":"2014","unstructured":"Molendijk, I., Nuij, V. J., van der Meulen-de Jong, A. E. & van der Woude, C. J. Disappointing durable remission rates in complex Crohn\u2019s disease fistula. Inflamm. Bowel Dis. 20, 2022\u20132028 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"1226_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-026-01357-7","author":"JD Isaacs","year":"2026","unstructured":"Isaacs, J. D. Immune reset and immune retune: approaching cure? Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/s41584-026-01357-7 (2026).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1226_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1634090","volume":"16","author":"F Gaspal","year":"2025","unstructured":"Gaspal, F., Narendran, P., Ng, S. T. H., Price, M. J. & Wraith, D. C. \u2018Immune reset plus\u2019: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases. Front. Immunol. 16, 1634090 (2025).","journal-title":"Front. Immunol."},{"key":"1226_CR20","unstructured":"Press release: Tr1X announces FDA clearance of IND application for TRX103, an allogeneic engineered Tr1 Treg cell therapy for treatment-refractory Crohn\u2019s disease. TRX Bio https:\/\/www.globenewswire.com\/news-release\/2024\/08\/07\/2925903\/0\/en\/Tr1X-Announces-FDA-Clearance-of-IND-Application-for-TRX103-an-Allogeneic-Engineered-Tr1-Treg-Cell-Therapy-for-Treatment-Refractory-Crohn-s-Disease.html (2024)."},{"key":"1226_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","volume":"143","author":"P Desreumaux","year":"2012","unstructured":"Desreumaux, P. et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn\u2019s disease. Gastroenterology 143, 1207\u20131217.e1201\u20131202 (2012).","journal-title":"Gastroenterology"},{"key":"1226_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gutjnl-2022-327075","volume":"72","author":"C Voskens","year":"2023","unstructured":"Voskens, C. et al. Autologous regulatory T cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis. Gut 72, 49\u201353 (2023).","journal-title":"Gut"},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/gutjnl-2015-309836","volume":"65","author":"A Jauregui-Amezaga","year":"2016","unstructured":"Jauregui-Amezaga, A. et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn\u2019s disease. Gut 65, 1456\u20131462 (2016).","journal-title":"Gut"},{"key":"1226_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/ecco-jcc\/jjx054","volume":"11","author":"A Lopez-Garcia","year":"2017","unstructured":"Lopez-Garcia, A. et al. Autologous haematopoietic stem cell transplantation for refractory Crohn\u2019s disease: efficacy in a single-centre cohort. J. Crohns Colitis 11, 1161\u20131168 (2017).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70452","volume":"15","author":"X Luo","year":"2025","unstructured":"Luo, X. et al. Reconstitution of T cell-mediated immunity by umbilical cord-derived mesenchymal stem cells in ulcerative colitis. Clin. Transl. Med. 15, e70452 (2025).","journal-title":"Clin. Transl. Med."},{"key":"1226_CR26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","volume":"388","author":"J Panes","year":"2016","unstructured":"Panes, J. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388, 1281\u20131290 (2016).","journal-title":"Lancet"},{"key":"1226_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJMc2508023","volume":"393","author":"F Muller","year":"2025","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis. N. Engl. J. Med. 393, 1239\u20131241 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1226_CR29","doi-asserted-by":"publisher","first-page":"90630","DOI":"10.18632\/oncotarget.21867","volume":"8","author":"K Chang","year":"2017","unstructured":"Chang, K., Song, J. Y. & Lim, D. S. Tolerogenic dendritic cell-based immunotherapy. Oncotarget 8, 90630\u201390631 (2017).","journal-title":"Oncotarget"},{"key":"1226_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13287-024-03878-y","volume":"15","author":"X Jiang","year":"2024","unstructured":"Jiang, X. et al. Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms. Stem Cell Res. Ther. 15, 272 (2024).","journal-title":"Stem Cell Res. Ther."},{"key":"1226_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.smim.2006.01.007","volume":"18","author":"M Battaglia","year":"2006","unstructured":"Battaglia, M., Gregori, S., Bacchetta, R. & Roncarolo, M. G. TR1 cells: from discovery to their clinical application. Semin. Immunol. 18, 120\u2013127 (2006).","journal-title":"Semin. Immunol."},{"key":"1226_CR32","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1226_CR33","first-page":"580","volume":"59","author":"DC Talbot","year":"1998","unstructured":"Talbot, D. C., Montes, A., Teh, W. L., Nandi, A. & Powles, R. L. Remission of Crohn\u2019s disease following allogeneic bone marrow transplant for acute leukaemia. Hosp. Med. 59, 580\u2013581 (1998).","journal-title":"Hosp. Med."},{"key":"1226_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/ajh.2830430223","volume":"43","author":"PE Drakos","year":"1993","unstructured":"Drakos, P. E., Nagler, A. & Or, R. Case of Crohn\u2019s disease in bone marrow transplantation. Am. J. Hematol. 43, 157\u2013158 (1993).","journal-title":"Am. J. Hematol."},{"key":"1226_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14750","volume":"64","author":"M Morita","year":"2022","unstructured":"Morita, M. et al. Intestinal outcome of bone marrow transplantation for monogenic inflammatory bowel disease. Pediatr. Int. 64, e14750 (2022).","journal-title":"Pediatr. Int."},{"key":"1226_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S2468-1253(17)30056-0","volume":"2","author":"JO Lindsay","year":"2017","unstructured":"Lindsay, J. O. et al. Autologous stem-cell transplantation in treatment-refractory Crohn\u2019s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol. Hepatol. 2, 399\u2013406 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1226_CR37","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2015.16700","volume":"314","author":"CJ Hawkey","year":"2015","unstructured":"Hawkey, C. J. et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. J. Am. Med. Assoc. 314, 2524\u20132534 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"1226_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2468-1253(23)00460-0","volume":"9","author":"JO Lindsay","year":"2024","unstructured":"Lindsay, J. O. et al. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn\u2019s disease (ASTIClite): an open-label, multicentre, randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 333\u2013345 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1226_CR39","doi-asserted-by":"publisher","unstructured":"Guisado, D. et al. Efficacy and safety of autologous hematopoietic stem cell transplantation in refractory Crohn\u2019s disease: outcomes from the international stem cell transplant consortium. J. Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae1190.0005 (2025).","DOI":"10.1093\/ecco-jcc\/jjae1190.0005"},{"key":"1226_CR40","first-page":"499","volume":"9","author":"A Gupta","year":"2024","unstructured":"Gupta, A., Guisado, D., Ricart, E., Colombel, J. F. & Cohen, L. Haematopoietic stem-cell transplantation in Crohn\u2019s disease. LancetGastroenterol. Hepatol. 9, 499\u2013500 (2024).","journal-title":"LancetGastroenterol. Hepatol."},{"key":"1226_CR41","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/ecco-jcc\/jjae076","volume":"18","author":"A Giordano","year":"2024","unstructured":"Giordano, A. et al. Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn\u2019s disease patients. J. Crohns Colitis 18, 1701\u20131712 (2024).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR42","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa0907206","volume":"361","author":"EO Glocker","year":"2009","unstructured":"Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033\u20132045 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR43","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.cgh.2025.03.018","volume":"23","author":"A Baccarella","year":"2025","unstructured":"Baccarella, A. et al. Outcomes of allogeneic hematopoietic stem cell transplant in monogenic inflammatory bowel disease. Clin.Gastroenterol. Hepatol. 23, 2242\u20132252 (2025).","journal-title":"Clin.Gastroenterol. Hepatol."},{"key":"1226_CR44","first-page":"39","volume":"15","author":"AN Ananthakrishnan","year":"2018","unstructured":"Ananthakrishnan, A. N. et al. Environmental triggers in IBD: a review of progress and evidence. Gastroenterol. Hepatol. 15, 39\u201349 (2018).","journal-title":"Gastroenterol. Hepatol."},{"key":"1226_CR45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins, L. et al. Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119\u2013124 (2012).","journal-title":"Nature"},{"key":"1226_CR46","first-page":"107","volume":"64","author":"LC Arruda","year":"2016","unstructured":"Arruda, L. C. et al. Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases. Curr. Res. Transl. Med. 64, 107\u2013113 (2016).","journal-title":"Curr. Res. Transl. Med."},{"key":"1226_CR47","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/gutjnl-2018-317878","volume":"68","author":"M Allez","year":"2019","unstructured":"Allez, M. et al. T cell clonal expansions in ileal Crohn\u2019s disease are associated with smoking behaviour and postoperative recurrence. Gut 68, 1961\u20131970 (2019).","journal-title":"Gut"},{"key":"1226_CR48","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","volume":"178","author":"JC Martin","year":"2019","unstructured":"Martin, J. C. et al. Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy. Cell 178, 1493\u20131508.e1420 (2019).","journal-title":"Cell"},{"key":"1226_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41590-018-0298-5","volume":"20","author":"S Zundler","year":"2019","unstructured":"Zundler, S. et al. Hobit- and Blimp-1-driven CD4+ tissue-resident memory T cells control chronic intestinal inflammation. Nat. Immunol. 20, 288\u2013300 (2019).","journal-title":"Nat. Immunol."},{"key":"1226_CR50","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/ecco-jcc\/jjy203","volume":"13","author":"AM Corraliza","year":"2019","unstructured":"Corraliza, A. M. et al. Differences in peripheral and tissue immune cell populations following haematopoietic stem cell transplantation in Crohn\u2019s disease patients. J. Crohns Colitis 13, 634\u2013647 (2019).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR51","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/gutjnl-2024-333558","volume":"74","author":"D Guisado","year":"2025","unstructured":"Guisado, D. et al. Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn\u2019s disease. Gut 74, 894\u2013905 (2025).","journal-title":"Gut"},{"key":"1226_CR52","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ueg2.12673","volume":"13","author":"C Taxonera","year":"2025","unstructured":"Taxonera, C. et al. Darvadstrocel for complex perianal fistulas in Crohn\u2019s disease: a systematic review and meta-analysis. United European Gastroenterol. J. 13, 416\u2013426 (2025).","journal-title":"United European Gastroenterol. J."},{"key":"1226_CR53","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2017.12.020","volume":"154","author":"J Panes","year":"2018","unstructured":"Panes, J. et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn\u2019s disease. Gastroenterology 154, 1334\u20131342 (2018).","journal-title":"Gastroenterology"},{"key":"1226_CR54","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","volume":"18","author":"Z Serclova","year":"2024","unstructured":"Serclova, Z. et al. OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn\u2019s disease: results from the global ADMIRE-CD II phase 3 study. J. Crohns Colitis 18, i34\u2013i35 (2024).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR55","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1053\/j.gastro.2025.12.033","volume":"170","author":"JF Colombel","year":"2026","unstructured":"Colombel, J. F. et al. Darvadstrocel in patients with Crohn\u2019s disease with complex perianal fistulas: the ADMIRE CD II phase 3 randomized trial. Gastroenterology 170, 1562\u20131570 (2026).","journal-title":"Gastroenterology"},{"key":"1226_CR56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13287-024-03779-0","volume":"15","author":"AJM Pronk","year":"2024","unstructured":"Pronk, A. J. M. et al. Mesenchymal stem cell therapy for therapy refractory complex Crohn\u2019s perianal fistulas: a case series. Stem Cell Res. Ther. 15, 161 (2024).","journal-title":"Stem Cell Res. Ther."},{"key":"1226_CR57","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1089\/scd.2024.0102","volume":"33","author":"H Jafar","year":"2024","unstructured":"Jafar, H. et al. Safety and potential efficacy of expanded umbilical cord-derived mesenchymal stromal cells in luminal ulcerative colitis patients. Stem Cells Dev. 33, 645\u2013651 (2024).","journal-title":"Stem Cells Dev."},{"key":"1226_CR58","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/codi.16239","volume":"24","author":"AL Lightner","year":"2022","unstructured":"Lightner, A. L. et al. A phase IB\/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis. Colorectal Dis. 24, 1358\u20131370 (2022).","journal-title":"Colorectal Dis."},{"key":"1226_CR59","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/stem.2948","volume":"37","author":"VJ Mehler","year":"2019","unstructured":"Mehler, V. J., Burns, C. & Moore, M. L. Concise review: exploring immunomodulatory features of mesenchymal stromal cells in humanized mouse models. Stem Cells 37, 298\u2013305 (2019).","journal-title":"Stem Cells"},{"key":"1226_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637725","volume":"9","author":"L Muller","year":"2021","unstructured":"Muller, L. et al. Immunomodulatory properties of mesenchymal stromal cells: an update. Front. Cell Dev. Biol. 9, 637725 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1226_CR61","doi-asserted-by":"publisher","first-page":"12204","DOI":"10.7150\/thno.47683","volume":"10","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice. Theranostics 10, 12204\u201312222 (2020).","journal-title":"Theranostics"},{"key":"1226_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1400347","volume":"12","author":"AB Cesnik","year":"2024","unstructured":"Cesnik, A. B. & Svajger, U. The issue of heterogeneity of MSC-based advanced therapy medicinal products \u2014 a review. Front. Cell Dev. Biol. 12, 1400347 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"1226_CR63","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/sctm.19-0044","volume":"8","author":"I Mastrolia","year":"2019","unstructured":"Mastrolia, I. et al. Challenges in clinical development of mesenchymal stromal\/stem cells: concise review. Stem Cells Transl. Med. 8, 1135\u20131148 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"1226_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716499","volume":"12","author":"J Jacobse","year":"2021","unstructured":"Jacobse, J., Li, J., Rings, E., Samsom, J. N. & Goettel, J. A. Intestinal regulatory T cells as specialized tissue-restricted immune cells in intestinal immune homeostasis and disease. Front. Immunol. 12, 716499 (2021).","journal-title":"Front. Immunol."},{"key":"1226_CR65","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.190.7.995","volume":"190","author":"C Asseman","year":"1999","unstructured":"Asseman, C., Mauze, S., Leach, M. W., Coffman, R. L. & Powrie, F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190, 995\u20131004 (1999).","journal-title":"J. Exp. Med."},{"key":"1226_CR66","doi-asserted-by":"publisher","first-page":"a018341","DOI":"10.1101\/cshperspect.a018341","volume":"5","author":"OJ Harrison","year":"2013","unstructured":"Harrison, O. J. & Powrie, F. M. Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb. Perspect. Biol. 5, a018341 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1226_CR67","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/ijms19030730","volume":"19","author":"GR Lee","year":"2018","unstructured":"Lee, G. R. The balance of TH17 versus Treg cells in autoimmunity. Int. J. Mol. Sci. 19, 730 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1226_CR68","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5217\/ir.2023.00029","volume":"21","author":"CH Lee","year":"2023","unstructured":"Lee, C. H., Koh, S. J., Radi, Z. A. & Habtezion, A. Animal models of inflammatory bowel disease: novel experiments for revealing pathogenesis of colitis, fibrosis, and colitis-associated colon cancer. Intest. Res. 21, 295\u2013305 (2023).","journal-title":"Intest. Res."},{"key":"1226_CR69","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/gut.2005.072801","volume":"55","author":"MC Fantini","year":"2006","unstructured":"Fantini, M. C. et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress TH1 mediated experimental colitis. Gut 55, 671\u2013680 (2006).","journal-title":"Gut"},{"key":"1226_CR70","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1053\/j.gastro.2005.03.043","volume":"128","author":"J Maul","year":"2005","unstructured":"Maul, J. et al. Peripheral and intestinal regulatory CD4+ CD25high T cells in inflammatory bowel disease. Gastroenterology 128, 1868\u20131878 (2005).","journal-title":"Gastroenterology"},{"key":"1226_CR71","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3109\/00365521.2011.551887","volume":"46","author":"DH Reikvam","year":"2011","unstructured":"Reikvam, D. H. et al. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn\u2019s disease patients. Scand. J. Gastroenterol. 46, 550\u2013560 (2011).","journal-title":"Scand. J. Gastroenterol."},{"key":"1226_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53240-z","volume":"9","author":"AK Kannan","year":"2019","unstructured":"Kannan, A. K. et al. IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases. Sci. Rep. 9, 17675 (2019).","journal-title":"Sci. Rep."},{"key":"1226_CR73","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura, A. & Kishimoto, T. IL-6: regulator of Treg\/TH17 balance. Eur. J. Immunol. 40, 1830\u20131835 (2010).","journal-title":"Eur. J. Immunol."},{"key":"1226_CR74","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/gutjnl-2019-319850","volume":"69","author":"JN Clough","year":"2020","unstructured":"Clough, J. N., Omer, O. S., Tasker, S., Lord, G. M. & Irving, P. M. Regulatory T-cell therapy in Crohn\u2019s disease: challenges and advances. Gut 69, 942\u2013952 (2020).","journal-title":"Gut"},{"key":"1226_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250007","volume":"53","author":"M Laukova","year":"2023","unstructured":"Laukova, M. & Glatman Zaretsky, A. Regulatory T cells as a therapeutic approach for inflammatory bowel disease. Eur. J. Immunol. 53, e2250007 (2023).","journal-title":"Eur. J. Immunol."},{"key":"1226_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-306919","author":"JB Canavan","year":"2015","unstructured":"Canavan, J. B. et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease. Gut https:\/\/doi.org\/10.1136\/gutjnl-2014-306919 (2015).","journal-title":"Gut"},{"key":"1226_CR77","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1097\/MIB.0000000000001192","volume":"23","author":"CJ Voskens","year":"2017","unstructured":"Voskens, C. J. et al. Characterization and expansion of autologous GMP-ready regulatory T cells for TREG-based cell therapy in patients with ulcerative colitis. Inflamm. Bowel Dis. 23, 1348\u20131359 (2017).","journal-title":"Inflamm. Bowel Dis."},{"key":"1226_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049208","volume":"11","author":"CJ Voskens","year":"2021","unstructured":"Voskens, C. J. et al. Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. BMJ Open 11, e049208 (2021).","journal-title":"BMJ Open"},{"key":"1226_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329818","author":"KA Ullrich","year":"2023","unstructured":"Ullrich, K. A. et al. IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells. Gut https:\/\/doi.org\/10.1136\/gutjnl-2023-329818 (2023).","journal-title":"Gut"},{"key":"1226_CR80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2024.10.003","volume":"168","author":"TM Muller","year":"2025","unstructured":"Muller, T. M. et al. Engineering therapeutic regulatory T cells to overexpress G Protein-coupled receptor 15 improves functional fitness for in vivo gut homing. Gastroenterology 168, 389\u2013392.e384 (2025).","journal-title":"Gastroenterology"},{"key":"1226_CR81","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ecco-jcc\/jjae012","volume":"18","author":"S Schramm","year":"2024","unstructured":"Schramm, S. et al. Blocking GPR15 counteracts Integrin-dependent T cell gut homing in vivo. J. Crohns Colitis 18, 1162\u20131172 (2024).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR82","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1053\/j.gastro.2023.03.230","volume":"165","author":"JR Allegretti","year":"2023","unstructured":"Allegretti, J. R., Mitsialis, V., Canavan, J. B., Low-Dose, I. L. U. C. S. G. & Snapper, S. B. Low-dose interleukin 2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology 165, 492\u2013495.e492 (2023).","journal-title":"Gastroenterology"},{"key":"1226_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149775","volume":"53","author":"J Geginat","year":"2023","unstructured":"Geginat, J. et al. Eomesodermin-expressing type 1 regulatory (EOMES+TR1)-like T cells: basic biology and role in immune-mediated diseases. Eur. J. Immunol. 53, e2149775 (2023).","journal-title":"Eur. J. Immunol."},{"key":"1226_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1509956","volume":"15","author":"Y Bulliard","year":"2024","unstructured":"Bulliard, Y. et al. From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases. Front. Immunol. 15, 1509956 (2024).","journal-title":"Front. Immunol."},{"key":"1226_CR85","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1053\/j.gastro.2019.09.002","volume":"157","author":"L Cook","year":"2019","unstructured":"Cook, L. et al. Suppressive and gut-reparative functions of human type 1 T regulatory cells. Gastroenterology 157, 1584\u20131598 (2019).","journal-title":"Gastroenterology"},{"key":"1226_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2520747122","volume":"123","author":"E Ansaldo","year":"2026","unstructured":"Ansaldo, E. et al. T-bet-expressing TR1 cells driven by dietary signals dominate the small intestinal immune landscape. Proc. Natl Acad. Sci. USA 123, e2520747122 (2026).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1226_CR87","doi-asserted-by":"publisher","first-page":"456","DOI":"10.4049\/immunohorizons.2200071","volume":"7","author":"JY Zhou","year":"2023","unstructured":"Zhou, J. Y. et al. Intestinal TR1 cells confer protection against colitis in the absence of Foxp3+ regulatory T cell-derived IL-10. ImmunoHorizons 7, 456\u2013466 (2023).","journal-title":"ImmunoHorizons"},{"key":"1226_CR88","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jgg.2022.05.005","volume":"49","author":"G Qu","year":"2022","unstructured":"Qu, G. et al. Current status and perspectives of regulatory T cell-based therapy. J. Genet. Genomics 49, 599\u2013611 (2022).","journal-title":"J. Genet. Genomics"},{"key":"1226_CR89","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2018.00233","volume":"9","author":"S Gregori","year":"2018","unstructured":"Gregori, S. & Roncarolo, M. G. Engineered T regulatory type 1 cells for clinical application. Front. Immunol. 9, 233 (2018).","journal-title":"Front. Immunol."},{"key":"1226_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01349-4","author":"J Avouac","year":"2026","unstructured":"Avouac, J. et al. Roads and detours for CAR T cell therapy in autoimmune diseases. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01349-4 (2026).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1226_CR91","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s10238-025-01820-x","volume":"25","author":"N Sueangoen","year":"2025","unstructured":"Sueangoen, N. & Prasongtanakij, S. Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer. Clin. Exp. Med. 25, 274 (2025).","journal-title":"Clin. Exp. Med."},{"key":"1226_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1611984","volume":"16","author":"Y He","year":"2025","unstructured":"He, Y. et al. CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed\/refractory follicular lymphoma: a literature review and meta-analysis. Front. Immunol. 16, 1611984 (2025).","journal-title":"Front. Immunol."},{"key":"1226_CR93","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li, M. et al. Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N. Engl. J. Med. 391, 376\u2013378 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03937-8","author":"J Feng","year":"2025","unstructured":"Feng, J. et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03937-8 (2025).","journal-title":"Nat. Med."},{"key":"1226_CR95","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2015-310187","volume":"66","author":"A Marchal-Bressenot","year":"2017","unstructured":"Marchal-Bressenot, A. et al. Development and validation of the Nancy histological index for UC. Gut 66, 43\u201349 (2017).","journal-title":"Gut"},{"key":"1226_CR96","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00428-005-0136-7","volume":"448","author":"Y Jinno","year":"2006","unstructured":"Jinno, Y. et al. Infiltration of CD19+ plasma cells with frequent labeling of Ki-67 in corticosteroid-resistant active ulcerative colitis. Virchows Arch. 448, 412\u2013421 (2006).","journal-title":"Virchows Arch."},{"key":"1226_CR97","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1016\/j.ajpath.2016.07.026","volume":"186","author":"GJ Randolph","year":"2016","unstructured":"Randolph, G. J. et al. Lymphoid aggregates remodel lymphatic collecting vessels that serve mesenteric lymph nodes in crohn disease. Am. J. Pathol. 186, 3066\u20133073 (2016).","journal-title":"Am. J. Pathol."},{"key":"1226_CR98","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230079","volume":"221","author":"S Tejedor Vaquero","year":"2024","unstructured":"Tejedor Vaquero, S. et al. Immunomolecular and reactivity landscapes of gut IgA subclasses in homeostasis and inflammatory bowel disease. J. Exp. Med. 221, e20230079 (2024).","journal-title":"J. Exp. Med."},{"key":"1226_CR99","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/apt.13641","volume":"43","author":"RS Choung","year":"2016","unstructured":"Choung, R. S. et al. Serologic microbial associated markers can predict Crohn\u2019s disease behaviour years before disease diagnosis. Aliment. Pharmacol. Ther. 43, 1300\u20131310 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1226_CR100","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2008.12.046","volume":"136","author":"X Han","year":"2009","unstructured":"Han, X. et al. Granulocyte\u2013macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn\u2019s disease. Gastroenterology 136, 1261\u20131271 (2009).","journal-title":"Gastroenterology"},{"key":"1226_CR101","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.4049\/jimmunol.150.6.2487","volume":"150","author":"KM Das","year":"1993","unstructured":"Das, K. M., Dasgupta, A., Mandal, A. & Geng, X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J. Immunol. 150, 2487\u20132493 (1993).","journal-title":"J. Immunol."},{"key":"1226_CR102","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","volume":"58","author":"H Yoshida","year":"2023","unstructured":"Yoshida, H. et al. Anti-integrin \u03b1V\u03b26 autoantibodies in patients with primary sclerosing cholangitis. J. Gastroenterol. 58, 778\u2013789 (2023).","journal-title":"J. Gastroenterol."},{"key":"1226_CR103","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1053\/j.gastro.2022.12.042","volume":"164","author":"AE Livanos","year":"2023","unstructured":"Livanos, A. E. et al. Anti-Integrin \u03b1V\u03b26 autoantibodies are a novel biomarker that antedate ulcerative colitis. Gastroenterology 164, 619\u2013629 (2023).","journal-title":"Gastroenterology"},{"key":"1226_CR104","doi-asserted-by":"publisher","first-page":"jjae131","DOI":"10.1093\/ecco-jcc\/jjae131","volume":"19","author":"D Roth","year":"2025","unstructured":"Roth, D. et al. Integrin \u03b1V\u03b26: autoantigen and driver of epithelial remodeling in colon and bile ducts in primary sclerosing cholangitis and inflammatory bowel disease. J. Crohns Colitis 19, jjae131 (2025).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR105","doi-asserted-by":"publisher","first-page":"jjaf062","DOI":"10.1093\/ecco-jcc\/jjaf062","volume":"19","author":"E Pertsinidou","year":"2025","unstructured":"Pertsinidou, E. et al. Anti-integrin \u03b1V\u03b26 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: a cross-sectional and longitudinal study defining a specific disease phenotype. J. Crohns Colitis 19, jjaf062 (2025).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR106","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","volume":"28","author":"M Uzzan","year":"2022","unstructured":"Uzzan, M. et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat. Med. 28, 766\u2013779 (2022).","journal-title":"Nat. Med."},{"key":"1226_CR107","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/gut.2010.225482","volume":"60","author":"K Leiper","year":"2011","unstructured":"Leiper, K. et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60, 1520\u20131526 (2011).","journal-title":"Gut"},{"key":"1226_CR108","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ibd.20215","volume":"13","author":"M Goetz","year":"2007","unstructured":"Goetz, M., Atreya, R., Ghalibafian, M., Galle, P. R. & Neurath, M. F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13, 1365\u20131368 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"1226_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13577","volume":"1415","author":"M Uzzan","year":"2018","unstructured":"Uzzan, M. et al. Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells. Ann. N. Y. Acad. Sci. 1415, 5\u201310 (2018).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1226_CR110","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/ibd\/izad224","volume":"30","author":"EK Boden","year":"2024","unstructured":"Boden, E. K. et al. Vedolizumab efficacy is associated with decreased intracolonic dendritic cells, not memory T cells. Inflamm. Bowel Dis. 30, 704\u2013717 (2024).","journal-title":"Inflamm. Bowel Dis."},{"key":"1226_CR111","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ecco-jcc\/jjaa178","volume":"15","author":"M Veny","year":"2021","unstructured":"Veny, M. et al. Dissecting common and unique effects of anti-\u03b14\u03b27 and anti-tumor necrosis factor treatment in ulcerative colitis. J. Crohns Colitis 15, 441\u2013452 (2021).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR112","doi-asserted-by":"publisher","DOI":"10.1155\/cdr\/7230505","volume":"2025","author":"H Li","year":"2025","unstructured":"Li, H. et al. Fibroblast activation protein-targeted CAR-T cells induce apoptosis in murine cardiac myofibroblasts. Cardiovasc. Ther. 2025, 7230505 (2025).","journal-title":"Cardiovasc. Ther."},{"key":"1226_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1469251","volume":"15","author":"LL Li","year":"2024","unstructured":"Li, L. L. et al. Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up. Front. Immunol. 15, 1469251 (2024).","journal-title":"Front. Immunol."},{"key":"1226_CR114","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000247","volume":"7","author":"L Wang","year":"2025","unstructured":"Wang, L. & Qiu, S. CD7 CAR-T therapy: current developments, improvements, and dilemmas. Blood Sci. 7, e00247 (2025).","journal-title":"Blood Sci."},{"key":"1226_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1478888","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis. Front. Oncol. 14, 1478888 (2024).","journal-title":"Front. Oncol."},{"key":"1226_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1625166","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. CAR-T therapy: pioneering a new era in the treatment of autoimmune diseases. Front. Immunol. 16, 1625166 (2025).","journal-title":"Front. Immunol."},{"key":"1226_CR117","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ecco-jcc\/jjad212.0002","volume":"18","author":"Y Cui","year":"2024","unstructured":"Cui, Y. et al. IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn\u2019s disease. J. Crohns Colitis 18, i3 (2024).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR118","first-page":"jjae135","volume":"19","author":"Y Cui","year":"2025","unstructured":"Cui, Y. et al. IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease. J. Crohns Colitis 19, jjae135 (2025).","journal-title":"J. Crohns Colitis"},{"key":"1226_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007381","volume":"96","author":"X Qiu","year":"2017","unstructured":"Qiu, X. et al. Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn\u2019s disease: a systematic review and meta-analysis. Medicine 96, e7381 (2017).","journal-title":"Medicine"},{"key":"1226_CR120","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10565-024-09921-1","volume":"40","author":"X Xu","year":"2024","unstructured":"Xu, X. et al. hucMSC-Ex alleviates inflammatory bowel disease in mice by enhancing M2-type macrophage polarization via the METTL3\u2013Slc37a2\u2013YTHDF1 axis. Cell Biol. Toxicol. 40, 74 (2024).","journal-title":"Cell Biol. Toxicol."},{"key":"1226_CR121","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jcis.2024.05.162","volume":"671","author":"C Deng","year":"2024","unstructured":"Deng, C. et al. Exosomes derived from mesenchymal stem cells containing berberine for ulcerative colitis therapy. J. Colloid Interface Sci. 671, 354\u2013373 (2024).","journal-title":"J. Colloid Interface Sci."},{"key":"1226_CR122","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s13287-025-04695-7","volume":"16","author":"L Tian","year":"2025","unstructured":"Tian, L. et al. Therapeutic evaluation of iPSC-derived CD146+ mesenchymal stem cells in ulcerative colitis: biological properties and potential mechanisms. Stem Cell Res. Ther. 16, 564 (2025).","journal-title":"Stem Cell Res. Ther."},{"key":"1226_CR123","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ibd.20927","volume":"15","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler, F. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease. Inflamm. Bowel Dis. 15, 1295\u20131301 (2009).","journal-title":"Inflamm. Bowel Dis."},{"key":"1226_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1604483","volume":"16","author":"J Stoops","year":"2025","unstructured":"Stoops, J., Morton, T., Powell, J., Pace, A. L. & Bluestone, J. A. Treg cell therapy manufacturability: current state of the art, challenges and new opportunities. Front. Immunol. 16, 1604483 (2025).","journal-title":"Front. Immunol."},{"key":"1226_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1698442","volume":"15","author":"JE Garcia-Robledo","year":"2025","unstructured":"Garcia-Robledo, J. E. et al. Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance. Front. Oncol. 15, 1698442 (2025).","journal-title":"Front. Oncol."},{"key":"1226_CR126","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR127","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028375","author":"F Muller","year":"2025","unstructured":"Muller, F. et al. Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood https:\/\/doi.org\/10.1182\/blood.2025028375 (2025).","journal-title":"Blood"},{"key":"1226_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149450","volume":"13","author":"S Zundler","year":"2023","unstructured":"Zundler, S. et al. Case report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. Front. Oncol. 13, 1149450 (2023).","journal-title":"Front. Oncol."},{"key":"1226_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01291-5","author":"A Bot","year":"2025","unstructured":"Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-025-01291-5 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1226_CR130","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"1226_CR131","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2509522","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMc2509522 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1226_CR132","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1080\/1750743X.2025.2572963","volume":"17","author":"Y Ma","year":"2025","unstructured":"Ma, Y., Qin, J., Liu, M. & Du, B. Allogeneic CAR-T cell therapy in autoimmune diseases. Immunotherapy 17, 1129\u20131143 (2025).","journal-title":"Immunotherapy"},{"key":"1226_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100749","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang, D. et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med 6, 100749 (2025).","journal-title":"Med"},{"key":"1226_CR134","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nri3661","volume":"14","author":"MF Neurath","year":"2014","unstructured":"Neurath, M. F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329\u2013342 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"1226_CR135","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","volume":"387","author":"I Cleynen","year":"2016","unstructured":"Cleynen, I. et al. Inherited determinants of Crohn\u2019s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387, 156\u2013167 (2016).","journal-title":"Lancet"},{"key":"1226_CR136","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1046\/j.1365-2141.1998.01059.x","volume":"103","author":"A Kashyap","year":"1998","unstructured":"Kashyap, A. & Forman, S. J. Autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma resulting in long-term remission of coincidental Crohn\u2019s disease. Br. J. Haematol. 103, 651\u2013652 (1998).","journal-title":"Br. J. Haematol."},{"key":"1226_CR137","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/00365520252903198","volume":"37","author":"JD Soderholm","year":"2002","unstructured":"Soderholm, J. D., Malm, C., Juliusson, G. & Sjodahl, R. Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand. J. Gastroenterol. 37, 613\u2013616 (2002).","journal-title":"Scand. J. Gastroenterol."},{"key":"1226_CR138","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1568-9972(02)00058-7","volume":"1","author":"RM Craig","year":"2002","unstructured":"Craig, R. M. Autologous hematopoietic stem cell transplantation for Crohn\u2019s disease. Autoimmun. Rev. 1, 244\u2013249 (2002).","journal-title":"Autoimmun. Rev."},{"key":"1226_CR139","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.bmt.1704134","volume":"32","author":"W Kreisel","year":"2003","unstructured":"Kreisel, W. et al. Complete remission of Crohn\u2019s disease after high-dose cyclophosphamide and autologous stem cell transplantation. Bone Marrow Transplant. 32, 337\u2013340 (2003).","journal-title":"Bone Marrow Transplant."},{"key":"1226_CR140","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.gastro.2005.01.015","volume":"128","author":"L Barkholt","year":"2005","unstructured":"Barkholt, L. & Lofberg, R. Resetting the immune system in refractory Crohn\u2019s disease: is autologous hematopoietic stem cell transplantation the way forward? Gastroenterology 128, 786\u2013789 (2005).","journal-title":"Gastroenterology"},{"key":"1226_CR141","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2008.11.041","volume":"136","author":"MA Gonzalez","year":"2009","unstructured":"Gonzalez, M. A., Gonzalez-Rey, E., Rico, L., Buscher, D. & Delgado, M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136, 978\u2013989 (2009).","journal-title":"Gastroenterology"},{"key":"1226_CR142","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1136\/gut.2008.168534","volume":"58","author":"E Gonzalez-Rey","year":"2009","unstructured":"Gonzalez-Rey, E. et al. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut 58, 929\u2013939 (2009).","journal-title":"Gut"},{"key":"1226_CR143","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1007\/s10350-005-0052-6","volume":"48","author":"D Garcia-Olmo","year":"2005","unstructured":"Garcia-Olmo, D. et al. A phase I clinical trial of the treatment of Crohn\u2019s fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum 48, 1416\u20131423 (2005).","journal-title":"Dis. Colon Rectum"},{"key":"1226_CR144","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/DCR.0b013e3181973487","volume":"52","author":"D Garcia-Olmo","year":"2009","unstructured":"Garcia-Olmo, D. et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis. Colon Rectum 52, 79\u201386 (2009).","journal-title":"Dis. Colon Rectum"},{"key":"1226_CR145","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/MOH.0000000000000531","volume":"26","author":"SA Ng","year":"2019","unstructured":"Ng, S. A. & Sullivan, K. M. Application of stem cell transplantation in autoimmune diseases. Curr. Opin. Hematol. 26, 392\u2013398 (2019).","journal-title":"Curr. Opin. Hematol."},{"key":"1226_CR146","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/1750743X.2026.2668205","volume":"18","author":"HS Kapare","year":"2026","unstructured":"Kapare, H. S., Jadhav, R., Karwa, P. N., Bhole, R. P. & Labhade, S. Next-generation cancer immunotherapy: the promise of CAR T-cell therapy. Immunotherapy 18, 399\u2013420 (2026).","journal-title":"Immunotherapy"},{"key":"1226_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.114988","volume":"29","author":"DN Stein","year":"2026","unstructured":"Stein, D. N. & Gendelman, H. E. CAR Treg therapies for neurodegenerative diseases. iScience 29, 114988 (2026).","journal-title":"iScience"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01226-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:02:31Z","timestamp":1790251351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":147,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01226-4","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"11 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F.N. has served as an adviser for the following companies: Abbvie, Takeda, BMS, Novartis, PPM, Pentax, Boehringer and J&J. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}